Stocks · News reference
Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 5:05 PM
- Checked
- Aug 24, 2026, 5:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14) per share from the
Read original at benzingaCingulate Announces Publication Of CTx-1301 Comparative Bioavailability Study In CNS Drugs, Says Trimodal ADHD Candidate Showed Higher Late-Day Plasma Levels And Fewer Adverse Events vs. Bimodal Comparator
Read original at benzinga